Stereoselectivity in Drug Disposition and Metabolism: Concepts and Mechanisms

  • Bernard Testa
Part of the NATO ASI Series book series (NSSA, volume 221)


A proper grasp of the stereoselectivity of pharmacological processes must begin at the molecular level, and particularly with the various classes of stereoisomers encountered among bioactive compounds. These notions then lead to a direct understanding of chiral recognition and its manifold expressions.


Human Serum Albumin Chiral Recognition Enantiomeric Ratio Catalytic Step Configurational Isomer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aso Y., Yoshioka S., Shibazaki T. and Uchiyama M., 1988. The kinetics of the racemization of oxazepam in aqueous soultion. Chem. Pharm. Bull. 36: 1834.PubMedCrossRefGoogle Scholar
  2. Bellucci G., Berti G., Chiappe C., Lippi A. and Marioni F., 1987. The metabolism of carbamazepine in humans: steric course of the enzymatic hydrolysis of the 10,11-epoxide. J. Med. Chem. 30: 768.PubMedCrossRefGoogle Scholar
  3. Campbell D.B., 1990a. The development of chiral drugs. Acta Pharm. Nord. 2: 217.PubMedGoogle Scholar
  4. Campbell D.B., 1990b. Stereoselectivity in clinical pharmacokinetics and drug development. Eur. J. Drug Metab. Pharmacokin. 15: 1109.CrossRefGoogle Scholar
  5. Cobb D., Boehlert C., Lewis D. and Armstrong R.N., 1983. Stereoselectivity of isozyme C of glutathione S-transferase toward arene and azaarene oxides. Biochemistry 22: 805.PubMedCrossRefGoogle Scholar
  6. Crooks P.A. and Godin C.S., 1988. N-Methylation of nicotine enantiomers by human liver cytosol. J. Pharm. Pharmacol. 40: 153.PubMedCrossRefGoogle Scholar
  7. Cundy K.C., Crooks P.A. and Godin C.S., 1985. Remarkable substrate-inhibitor properties of nicotine enantiomers towards a guinea pig lung aromatic azaheterocycle N-methyltransferase. Biochem. Biophys. Res. Commun. 128: 312.PubMedCrossRefGoogle Scholar
  8. Dahl-Puustinen M.L., Dumont E. and Bertilsson L., 1989. Glucuronidation of E10-hydroxynortriptyline in human liver, kidney and intestine. Organ-specific differences in enantioselectivity. Drug Metab. Disposit. 17: 433.Google Scholar
  9. Holtzman J.L. and Thompson J.A., 1975. Metabolism of R-(+)- and S-(-)-pentobarbital by hepatic microsomes from males rats. Drug Metab.Disposit. 3: 113.Google Scholar
  10. Ichinose R. and Kurihara N., 1987. Intramolecular deuterium isotope effect and enantiotopic differentiation in oxidative demethylation of chiral [monomethylD3]methoxychlor in rat liver microsomes. Biochem. Pharmacol. 36: 3751.PubMedCrossRefGoogle Scholar
  11. Jamali F., Mehvar R. and Pasutto F.M., 1989. Enantioselective aspects of drug action and disposition: Therapeutic pitfalls. J. Pharm. Sci. 78: 695.PubMedCrossRefGoogle Scholar
  12. Jenner P. and Testa B. 1973. The influence of stereochemical factors on drug disposition. Drug Metab. Rev. 2 117.PubMedCrossRefGoogle Scholar
  13. Lightner D.A., Wijekoon W.M.D. and Zhang M.H., 1988. Understanding bilirubin conformation and binding. Circular dichroism of human serum albumin complexes with bilirubin and its esters. J. Biol. Chem. 263: 16669.Google Scholar
  14. Müller W.E., 1988. Stereoselective plasma protein binding of drugs. In: “Drug Stereochemistry, Analytical Methods and Pharmacology” ( I.W. Wainer and D.E. Drayer, eds), page 227. Dekker, New York.Google Scholar
  15. Oravcova J., Bystricky S. and Trnovec T., 1989. Different binding of propranolol enantiomers to human alphas-acid glycoprotein. Biochem. Pharmacol. 38: 2575.PubMedCrossRefGoogle Scholar
  16. Palmer K.H., Fowler M.S., Wall M.E., Rhodes L.S., Waddell W.J. and Baggett B., 1969. The metabolism of R(+)- and RS-pentobarbital. J. Pharmacol. Exp. Therap. 170: 355.Google Scholar
  17. Palmer K.H., Fowler M.S. and Wall M.E., 1970. Metabolism of optically active barbiturates. II. S(-)-pentobarbital. J. Pharmacol. Exp. Therap. 175: 38.Google Scholar
  18. Sugiyama K. and Trager W.F., 1986. Prochiral selectivity and intramolecular isotope effect in the cytochrome P-450 catalyzed w-hydroxylation of cumene. Biochemistry 25: 7336.PubMedCrossRefGoogle Scholar
  19. Testa B., 1979. “Principles of Organic Stereochemistry.” Dekker, New York.Google Scholar
  20. Testa B., 1984. Drugs? Drug research? Advances in drug research? Musings of a medicinal chemist. In “Advances in Drug Research ( B. Testa, ed.), Vol. 13, page 1. Academic Press, London.Google Scholar
  21. Testa B., 1986. Chiral aspects of drug metabolism. Trends Pharmacol. Sci. 7, 60CrossRefGoogle Scholar
  22. Testa B., 1988. Substrate and product stereoselectivity in monooxygenase-mediated drug activation and inactivation. Biochem. Pharmacol. 37, 85.PubMedCrossRefGoogle Scholar
  23. Testa B., 1989. Conceptual and mechanistic overview of stereoselective drug metabolism. In: “Xenobiotic Metabolism and Disposition” ( R. Kato, R.W. Estabrook and M.N.Cayen, eds), page 153. Taylor & Francis, London.Google Scholar
  24. Testa B., 1990a. Definitions and concepts in biochirality. In: “Chirality and Biological Activity” ( B. Holmstedt, H. Frank and B. Testa, eds), page 15. Wiley-Liss, New York.Google Scholar
  25. Testa B., 1990b. Mechanisms of chiral recognition in pharmacology. The EassonStedman model revisited. Acta Pharm. Nord. 2: 137.Google Scholar
  26. Testa B. and Mayer J.M., 1988. Stereoselective drug metabolism and its significance in drug research. In: “Progress in Drug Research” ( E. Jucker ed.), Vol. 32, page 249. Birkhäuser, Basel.Google Scholar
  27. Trager W.F. and Testa B., 1985. Stereoselective drug disposition. In: “Drug Metabolism and Disposition: Considerations in Clinical Pharmacology” ( G.R. Wilkinson and M.D. Rawlins, eds), page 35. MTP Press, Lancaster.Google Scholar
  28. Tucker G.T. and Lennard M.S., 1990. Enantiomer specific pharmacokinetics. Pharmacol. Ther. 45: 309.PubMedCrossRefGoogle Scholar
  29. Vermeulen N.P.E. and Breimer D.D., 1983. Stereoselectivity in drug and xenobiotic metabolism. In: “Stereochemisty and Biological Activity of Drugs” ( E.J. Aridns, W. Soudijn and P.B.M.W.M. Timmermans, eds), page 33. Blackwell, Oxford.Google Scholar
  30. Visy J. and Simonyi M., 1989. The role of configuration and conformation in the binding of 2,3-benzodiazepines to human serum albumin. Chirality 1: 271.PubMedCrossRefGoogle Scholar
  31. Walle T and Walle UK, 1986. Pharmacoldnetic parameters obtained with racemates. Trends Pharmacol. Sci. 7, 155.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Bernard Testa
    • 1
  1. 1.Institut de Chimie Thérapeutique Ecole de PharmacieUniversité de LausanneLausanneSwitzerland

Personalised recommendations